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Metabolic reprogramming is an important driver of tumor progression; however, the metabolic regulators of 
tumor cell motility and metastasis are not understood. Here, we show that tumors maintain energy production 
under nutrient deprivation through the function of HSP90 chaperones compartmentalized in mitochondria. 
Using cancer cell lines, we found that mitochondrial HSP90 proteins, including tumor necrosis factor recep-
tor–associated protein-1 (TRAP-1), dampen the activation of the nutrient-sensing AMPK and its substrate 
UNC-51–like kinase (ULK1), preserve cytoskeletal dynamics, and release the cell motility effector focal adhe-
sion kinase (FAK) from inhibition by the autophagy initiator FIP200. In turn, this results in enhanced tumor 
cell invasion in low nutrients and metastatic dissemination to bone or liver in disease models in mice. More-
over, we found that phosphorylated ULK1 levels were correlated with shortened overall survival in patients 
with non–small cell lung cancer. These results demonstrate that mitochondrial HSP90 chaperones, including 
TRAP-1, overcome metabolic stress and promote tumor cell metastasis by limiting the activation of the nutri-
ent sensor AMPK and preventing autophagy.
Introduction
Metabolic reprogramming of tumors (1) is being increasingly rec-
ognized as an important disease driver, controlling various aspects 
of malignant development and progression (2). Although energeti-
cally unfavorable (3), cancer metabolism contributes to biomass 
expansion (4), oncogenic signaling (5), generation of biochemical 
defects that further the malignant phenotype (6, 7), and trans-
formation-associated epigenetic changes (8, 9). How tumor cells 
exploit a bioenergetics program to regulate malignant growth is 
beginning to emerge (10), but the regulators of this process are 
still elusive and their link to mechanisms of advanced disease, for 
instance, metastasis (11), has not been clearly elucidated.
In this context, tumors grow in acutely unfavorable environments, 
constantly exposed to oxidative stimuli and chronically depleted of 
oxygen and nutrients (12). Stress signals generated under these condi-
tions antagonize tumor growth via activation of tumor suppressors 
(13), including liver kinase B1 (LKB1)/AMPK (14), inhibition of onco-
genes, for instance, the mammalian target of rapamycin complex-1 
(mTORC1) (15), and induction of autophagy (16), a process of cel-
lular self digestion (17) that is often a barrier to transformation (18). 
Notwithstanding, nutrient-starved tumors circumvent these chal-
lenges and manage to acquire highly energetically demanding traits, 
such as invasiveness, which heralds metastatic and lethal disease (19).
In this study, we explored whether metabolic reprogramming 
of mitochondrial bioenergetics influenced mechanisms of tumor 
cell invasion and metastasis in vivo. We focused on a network of 
heat shock protein-90 (Hsp90) chaperones (20) that is preferen-
tially, if not exclusively, found in mitochondria of tumor cells (21). 
Functionally, these molecules oversee the organelle protein folding 
environment in tumors, antagonizing cyclophilin D–dependent 
(CypD-dependent) permeability transition (22), and maintaining 
energy production via retention of the glycolytic enzyme, hexoki-
nase II, to the mitochondrial outer membrane (23).
Results
Mitochondrial Hsp90 regulation of tumor cell motility. To begin investi-
gating a role of mitochondrial Hsp90s in tumor cell movements, 
we used Gamitrinib (GA mitochondrial matrix inhibitor), a small 
molecule Hsp90 ATPase antagonist engineered to accumulate 
selectively in mitochondria (24). In these experiments, noncyto-
toxic concentrations of Gamitrinib (23) suppressed the migration 
(Figure 1A and Supplemental Figure 1A; supplemental material 
available online with this article; doi:10.1172/JCI67841DS1), and 
invasion (Figure 1B and Supplemental Figure 1B) of tumor cell 
types. When tested in a more physiologic 3D model of cellular motil-
ity, Gamitrinib blocked tumor cell invasion in organotypic spher-
oids embedded in a collagen matrix (Figure 1C), with nearly com-
plete suppression of invasive length and invasive areas (Figure 1D). 
In control experiments, Gamitrinib did not reduce tumor cell pro-
liferation, compared with vehicle-treated culture cells (Figure 1E). 
Overall cell viability in a 3D microenvironment was also not affect-
ed by calcein-AM staining and 2-photon microscopy imaging of 
organotypic spheroids (Figure 1F). Consistent with these find-
ings, Gamitrinib also inhibited tumor cell migration in a wound 
closure assay at both 16- and 24-hour time intervals (Figure 1G). 
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This effect was specific for the tumor cells, as normal human 
fibroblasts treated with a broad range of Gamitrinib concentra-
tions showed no changed in migration in a wound closure assay at 
comparable time intervals (Figure 1H).
As an independent approach, we next knocked down the expres-
sion of one of the targets of Gamitrinib in mitochondria, the Hsp90-
like chaperone tumor necrosis factor receptor–associated protein-1 
(TRAP-1) (21). TRAP-1 silencing using pooled siRNAs (Figure 2A) 
reproduced the effect of Gamitrinib and suppressed tumor cell 
migration (Figure 2B). In contrast, TRAP-1 knockdown did not 
affect tumor cell proliferation, compared with cultures transfected 
with nontargeting siRNA (Figure 2C). To validate the specificity of 
these findings, we next silenced TRAP-1 in tumor cell types using 
individual siRNA sequences (Figure 2D). TRAP-1 knockdown under 
these conditions was also associated with significant inhibition of 
tumor cell migration (Figure 2E) and invasion (Figure 2F), whereas 
a control nontargeting siRNA was without effect.
Cellular requirements of mitochondrial Hsp90 control of tumor cell motility. 
Consistent with inhibition of cell motility, exposure of tumor cells to 
Gamitrinib suppressed actin cytoskeletal assembly, with appearance 
of a rounded cell morphology, devoid of stress fibers and filopodia, 
by fluorescence microscopy (Supplemental Figure 2). Accordingly, 
Gamitrinib treatment resulted in nearly complete loss of cytoskeletal 
lamella dynamics, as evidenced by single-cell, time-lapse videomicros-
copy analysis (Figure 3, A–C, and Supplemental Figure 3, A–C), with 
profound inhibition of ruffling frequency and retraction speed in 
tumor cells (Figure 3D). When analyzed for biochemical markers of 
cell motility, Gamitrinib-treated tumor cells exhibited loss of phos-
phorylation of focal adhesion kinase (FAK) (25) on its autophosphor-
ylation site, Tyr397 (26), and Src-phosphorylation site, Tyr925 (ref. 27 
and Figure 3E). Gamitrinib also inhibited the phosphorylation of 
other cell motility kinases, including Src on Tyr416 (Figure 3E), 
and of group I p21-activated kinases, Pak1,2 (28) on Ser199, 
Ser144, and Ser20 (Figure 3F). The activation of Rho family small 
GTPases, Rac1 and Cdc42, which coordinate actin cytoskeleton 
reorganization, lamellipodia protrusion and directional cell move-
ment (29), was also impaired by Gamitrinib treatment (Figure 3G). 
Instead, Akt or ERK phosphorylation was not affected, and the total 
levels of these kinases remained unchanged (Figure 3E).
We next asked whether modulation of signaling kinases participat-
ed in mitochondrial Hsp90 regulation of tumor cell motility. When 
transfected in tumor cells, recombinant FAK was phosphorylated, 
i.e., activated on Tyr397 and Tyr925, compared with the endog-
enous pool of the molecule (Figure 3H). Under these conditions, 
transfection of FAK nearly completely restored tumor cell migration 
and invasion in the presence of Gamitrinib (Figure 3I). In contrast, 
transfected FAK had no effect on tumor cell proliferation in the 
presence or absence of Gamitrinib (Figure 3J). Similarly, transfec-
tion of Src (Figure 3K), or constitutively active Cdc42Val12 mutant 
(Figure 3L) rescued the inhibition of tumor cell motility mediated 
by Gamitrinib (Figure 3, K and L). Conversely, transfection of con-
stitutively active RacVal12 did not reverse the effect of Gamitrinib on 
tumor cell invasion (Supplemental Figure 3D).
Bioenergetics requirement of mitochondrial Hsp90-directed tumor cell 
motility. In addition to opposing CypD-dependent permeability 
transition (21), mitochondrial Hsp90s maintain ATP production in 
tumor cells via retention of HK-II to the organelle outer membrane 
(23). To test whether this function in bioenergetics was important 
for tumor cell motility, we next treated tumor cells with the mito-
chondrial uncoupler carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) and looked for changes in cell motility. In these experi-
ments, CCCP suppressed tumor cell migration (Supplemental Fig-
ure 4, A and B) and invasion (Figure 4A), and abolished FAK phos-
phorylation on Tyr397 and Tyr925 (Figure 4B). Similar results were 
obtained in response to energy starvation induced by the nonhy-
drolyzable glucose analog 2 deoxyglucose (2-DG), which also sup-
pressed tumor cell migration (Supplemental Figure 4, A and B) and 
invasion (Figure 4A). Conversely, inhibition of Hsp90 chaperone 
activity in cytosol, but not mitochondria, with 17-allylamino deme-
thoxygeldanamicyn (17-AAG), (24) did not affect tumor cell migra-
tion or invasion (Figure 4A and Supplemental Figure 4, A and B). As 
control for these experiments, treatment of tumor cells with CCCP, 
2-DG, or Gamitrinib did not affect cell proliferation (Figure 4C) 
or cell death as determined by Trypan blue exclusion (Supplemen-
tal Figure 4C) compared with vehicle-treated cultures.
To identify a potential link between mitochondrial bioenergetics 
and tumor cell motility, we next exposed tumor cells to progressive-
ly lower glucose concentrations and looked at changes in metabolic 
markers. Consistent with current models of cellular responses to 
energy deprivation, glucose-starved LN229 cells exhibited increased 
phosphorylation of the energy sensor AMPK and concomitant acti-
vation of compensatory autophagy, as assessed by LC3 lipidation 
(Figure 4D). Silencing of TRAP-1 by siRNA considerably exacerbat-
ed these compensatory responses to energy deprivation (Figure 4D), 
demonstrating that TRAP-1 expression can dampen the activation 
of AMPK (23) and the induction of autophagy (30) during bioen-
ergetics stress. Similar results were obtained with pharmacologic 
inhibition of mitochondrial Hsp90s with Gamitrinib, which also 
increased AMPK phosphorylation during nutrient deprivation in 
a reaction partially reversed by addition of extracellular glucose 
(Figure 4E). Consistent with a role of mitochondrial Hsp90s in 
bioenergetics, siRNA silencing of TRAP-1 reduced tumor cell pro-
duction of ATP at limiting glucose concentrations, compared with 
control transfectants (Figure 4F). To begin identifying the require-
ments of this response, we next cultivated tumor cells in the pres-
ence of increasing concentrations of galactose that is only used for 
oxidative phosphorylation. In the presence of glucose or 50% galac-
tose, Gamitrinib did not significantly reduce the viability of LN229 
or PC3 cells compared with vehicle-treated cultures (Figure 4G). 
However, when grown in 100% galactose concentrations, Gami-
trinib induced nearly complete tumor cell death, whereas approxi-
mately 25% of cells in control cultures remained viable (Figure 4G).
We next performed reciprocal experiments and manipulated the 
expression of mitochondrial Hsp90s in normal NIH3T3 fibro-
blasts, which have low endogenous levels of these chaperones in 
mitochondria (21). Transfection of TRAP-1 in glucose-starving 
NIH3T3 cells attenuated phosphorylation of AMPK and of its 
substrate, acetyl-CoA carboxylase (ACC), compared with control 
transfectants (Figure 5A). This was associated with increased ATP 
production at limiting or no glucose concentrations, as opposed 
to vector transfectants that had low levels of ATP production 
(Figure 5B). When analyzed for cell motility, glucose- or amino 
acid–deprived NIH3T3 fibroblasts transfected with vector showed 
minimal invasion across Matrigel substrates (Figure 5C). Con-
versely, expression of TRAP-1 was sufficient to promote invasion 
of nutrient-deprived NIH3T3 cells (Figure 5C). In control experi-
ments, recombinant TRAP-1 expression did not significantly affect 
overall mitochondrial function by an MTT assay (Supplemental 
Figure 5A), cell viability by Trypan blue exclusion (Supplemental 
Figure 5B), or cell proliferation by direct cell counting (Figure 5D).
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Figure 1
Gamitrinib inhibition of tumor cell motility. (A and B) Gamitrinib-treated (Gam) (5 μM) PC3 cells were analyzed for cell migration (A) or inva-
sion (B). Mean ± SEM (n = 3), ***P < 0.0001. (C and D) 3D organotypic LN229 spheroids treated with vehicle or Gamitrinib (1.25–2.5 μM) were 
analyzed by phase contrast microscopy (C, top), and mask-inverted images (C, bottom) were used to quantify the length and area between the 
core and the invasive cores (D). Mean ± SEM (n = 3), *P = 0.0171–0.0295; ***P < 0.0001. Original magnification, ×20 (A and B); ×4 (C). (E) PC3 
cells were treated with vehicle or Gamitrinib as in A and B and analyzed for cell proliferation by direct cell counting. Mean ± SEM (n = 3). (F) 
LN229 spheroids were stained with calcein-AM (live cells, green) and Topro-3 (dead cells, blue) and analyzed by 2-photon microscopy. Original 
magnification, ×20. (G) PC3 cells were treated with vehicle or Gamitrinib (5 μM) and analyzed in a wound-closure assay after 16 or 24 hours. 
Representative micrographs (top) and quantification of cell motility (bottom) are shown. The leading front of cell migration is indicated by dotted 
lines. Mean ± SEM (n = 3), ***P < 0.0001–0.0004. Original magnification, ×5. (H) The experimental conditions are the same as in G except that 
normal human MRC-5 lung fibroblasts treated with vehicle or 2 concentrations of Gamitrinib (5–10 μM) were analyzed in a wound-closure assay 
after 16 or 24 hours. Original magnification, ×10.
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Control of tumor cell motility by AMPK-autophagy signaling. The data 
above have shown that AMPK phosphorylation correlates inverse-
ly with tumor and normal cell movements (Figure 5, A and C), 
and this response was further investigated. Silencing of AMPK 
using independent siRNA sequences partially restored tumor cell 
motility in the presence of Gamitrinib (Figure 6A), suggesting that 
AMPK activation was required for this response. siRNA knock-
down of the upstream AMPK activator and tumor suppressor, 
liver kinase B1 (LKB1) (Figure 6B and ref. 14), produced the same 
effect and rescued the inhibition of tumor cell invasion in the pres-
ence of Gamitrinib (Figure 6B). We next asked whether a require-
ment by LKB1/AMPK signaling in this pathway involved de novo 
energy production. In these experiments, Gamitrinib inhibited 
ATP production in tumor cells in a concentration-dependent man-
ner (Figure 6C). In contrast, siRNA silencing of AMPK or LKB1 
did not affect this response (Figure 6C). Next, we performed the 
reciprocal experiments and transfected tumor cells with vector or 
a constitutively active AMPK cDNA (AMPKCA) (Figure 6D). Forced 
expression of active AMPK was sufficient to reproduce the effect 
of Gamitrinib and inhibited tumor cell migration (Supplemental 
Figure 6A) and invasion (Figure 6E). Similar to the data reported 
above for LKB1/AMPK signaling (Figure 6C), constitutive expres-
sion of AMPKCA was not associated with significant changes in 
ATP production in tumor cells (Figure 6F). A control vector had 
no effect (Figure 6, E and F).
Next, we looked downstream of LKB1/AMPK signaling (14) 
and asked whether activation of the mTORC1 pathway (15), 
and/or autophagy (31) contributed to tumor cell motility. Con-
sistent with previous observations (15), inhibition of mTORC1 
with rapamycin suppressed 4EBP1 phosphorylation in tumor 
cells (Figure 6G). However, this had no effect on FAK phos-
phorylation (Figure 6G) or tumor cell migration (Figure 6H). 
Conversely, siRNA silencing of the essential autophagy gene atg5 
(Figure 6I) partially rescued tumor cell invasion in the presence 
of Gamitrinib (Figure 6J), indicating that activation of autoph-
agy was required for mitochondrial Hsp90 regulation of tumor 
cell motility. To validate the role of autophagy in this pathway, 
we next silenced the expression of TRAP-1 together with AMPK 
Figure 2
Mitochondrial chaperone TRAP-1 regulation of tumor cell motility. (A and B) The indicated tumor cell lines were transfected with control nontargeting 
(Ctrl) or TRAP-1–directed pooled siRNA and analyzed by Western blotting (A) or cell migration (B). Top panels, phase contrast microscopy. Bottom 
panels, quantification of cell migration. Mean ± SEM (n = 3). ***P < 0.0001. Original magnification, ×20. (C) The indicated tumor cell types were trans-
fected with control siRNA or siRNA directed to TRAP-1 and analyzed for cell proliferation by direct cell counting. Mean ± SEM (n = 3). (D) The indi-
cated tumor cell lines were transfected with control nontargeting siRNA or individual siRNA sequences to TRAP-1 and analyzed by Western blotting. 
(E and F) The indicated tumor cell types were transfected with control siRNA, individual siRNA sequences (nos. 1–4) to TRAP-1, or pooled siRNA 
(Pl) to TRAP-1 and analyzed for cell migration (E) or invasion (F) after 6 or 16 hours, respectively. Mean ± SEM (n = 3). *P = 0.031; ***P < 0.0001.
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Figure 3
Cellular requirements of mitochondrial Hsp90-directed tumor cell migration. (A) Representative images from video sequences of FBS-stimulated 
PC3 cells treated with vehicle or Gamitrinib (5 μM) and analyzed by real-time quantification of membrane ruffling (lamellipodia growth and 
retraction) by stroboscopic imaging. Scale bars: 16.2 μm length. (B) Stroboscopic images representing an area of analysis (white line in A) for 
the indicated time intervals. (C) Quantification of membrane ruffling frequency. Each bar corresponds to an individual cell. Broken lines, average 
values. (D) Average ruffling frequency (top), and quantification of speed of lamellipodia retraction in μm/min (bottom). Mean ± SEM (n = 15). 
***P < 0.0001. (E and F) Tumor cells treated with (+) or without (–) Gamitrinib (5 μM) were analyzed by Western blotting. p, phosphorylated. (G) 
Serum-starved A549 cells were stimulated with EGF (100 ng/ml, 2 minutes) or FBS (10%, 5 minutes), treated with (+) or without (–) Gamitrinib 
(5 μM), and analyzed for GTP-bound Rac1 or Cdc42. (H) PC3 cells were transfected with vector or cDNA encoding FAK and analyzed by Western 
blotting. p, phosphorylated. (I and J), PC3 cells transfected as in (H) and treated with (+) or without (–) Gamitrinib (5 μM) were analyzed for cell 
migration (left) or invasion (right) (I), or cell proliferation (J). Mean ± SEM (n = 3), ***P < 0.0001. (K and L) PC3 cells were transfected with vec-
tor or cDNAs encoding Src (K) or constitutively active Cdc42V12 mutant (L) and analyzed by Western blotting (left) or cell migration (right) in the 
presence (+) or absence (–) of Gamitrinib. Mean ± SEM (n = 3). **P = 0.0094.
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or atg5 (Supplemental Figure 6B) and we looked at changes in 
tumor cell motility. Simultaneous siRNA knockdown of AMPK 
or atg5 restored tumor cell migration in the presence of TRAP-1 
silencing by siRNA (Figure 6K). In these experiments, simultane-
ous knockdown of the autophagy initiating UNC-51–like kinase 
(ULK1) (32) also rescued the inhibitory effect of TRAP-1 silencing 
on tumor cell motility (Figure 6K).
ULK1-FIP200 regulation of tumor cell motility. The data above suggest 
that the upstream autophagy regulator, ULK1, controlled tumor 
cell motility during bioenergetics stress, and this possibility was 
next investigated. Consistent with this model, expression of con-
stitutively active AMPKCA in tumor cells resulted in strong phos-
phorylation of ULK1 on Ser555, which has been implicated as a 
potential AMPK phosphorylation site (refs. 31, 32, and Figure 7A). 
Figure 4
Metabolic stress control of tumor cell invasion. (A) PC3 cells were treated with Gamitrinib (5 μM), 17-AAG (5 μM), or CCCP (12.5 μM, or 2-DG 
(25 mM) and analyzed for cell invasion. Left, representative image of stained nuclei. Right, quantification. Mean ± SEM (n = 3). ***P < 0.0001. 
Original magnification, ×20. (B) PC3 cells were treated with Gamitrinib (1.25–5 μM) or CCCP (12.5 μM) and analyzed by Western blotting. (C) 
PC3 cells were treated as in A and analyzed for cell proliferation. Mean ± SEM (n = 3). (D) LN229 cells were transfected with control siRNA or 
TRAP-1–directed siRNA and analyzed by Western blotting with or without glucose (Glc). (E) LN229 cells were treated with vehicle or Gamitrinib 
(5 μM) and analyzed by Western blotting with or without glucose. (F) LN229 cells were transfected with control or TRAP-1–directed siRNA and 
analyzed for ATP production in the presence of the indicated concentrations of glucose. LU, luciferase units. Mean ± SEM (n = 3). (G) LN229 
(left) or PC3 (right) cells were treated with vehicle or Gamitrinib (5 μM), and analyzed for cell viability. Bars correspond to conditions of 100% 
glucose/0% galactose (Gal); 50% glucose/50% galactose, or 0% glucose/100% galactose. Mean ± SEM (n = 3), **P = 0.0018; ***P = 0.0007.
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In contrast, transfection of AMPKCA reduced ULK1 phosphoryla-
tion on Ser757, a potential mTORC1, (31) compared with vector 
control cells (Figure 7A). Src phosphorylation on Tyr416 was also 
attenuated by expression of constitutively active AMPK, whereas 
the total levels of the kinases were not affected (Figure 7A). We 
next asked whether energy starvation induced by Gamitrinib pro-
duced similar changes in ULK1 phosphorylation status. In these 
experiments, Gamitrinib induced early phosphorylation of AMPK 
and of its downstream substrate, ACC (Figure 7B), in agreement 
with recent observations (23). This was associated with significant 
changes in the ratio of AMPK (Ser555)/mTORC1 (Ser757) phos-
phorylation, with rapid, i.e., within 1 to 2 hours of treatment, phos-
phorylation of ULK1 on Ser555 and decreased phosphorylation on 
Ser757 (Figure 7B). Consistent with a model of ULK1 activation 
under these conditions, Gamitrinib also induced strong phosphor-
ylation of Raptor (33) on its inhibitory site, Ser792, whereas the 
total level of ULK1 was not affected (Figure 7B). As control, treat-
ment of tumor cells with the AMPK activator metformin produced 
similar results, with activation of AMPK and ACC, increased ULK1 
phosphorylation on Ser555, and inhibition of mTORC1 signal-
ing due to phosphorylation of Raptor on Ser792 and concomitant 
decreased phosphorylation of ULK1 on Ser757 (Figure 7B).
We next asked whether these responses were specific to modula-
tion of mitochondrial bioenergetics, and we treated tumor cells with 
17-AAG, which inhibits Hsp90 chaperone activity in the cytosol, but 
not mitochondria. At variance with Gamitrinib, 17-AAG did not 
affect AMPK or ACC phosphorylation in tumor cells (Figure 7C). 
Also, the ratio of ULK1 phosphorylation on the AMPK (Ser555)/
mTORC1 (Ser757) site was unaffected, as 17-AAG equally reduced 
ULK1 phosphorylation on Ser757 and Ser555 and Raptor remained 
unphosphorylated on Ser792 (Figure 7C). Although at the time 
points of this experiment, total ULK1 levels were not affected, a lon-
ger, 24-hour exposure of tumor cells to 17-AAG caused ULK1 deg-
radation (not shown), in agreement with recent observations (34).
We next silenced the expression of ULK1 by siRNA (Supplemental 
Figure 6C) and looked at biochemical and functional markers of cell 
motility in the presence or absence of Gamitrinib. ULK1 knockdown 
in tumor cells was sufficient to reactivate phosphorylation of FAK 
on Ty397 and Tyr925 and of Src on Tyr416 despite the presence of 
Gamitrinib (Figure 7D). Functionally, this was associated with rescue 
of tumor cell migration and invasion (Figure 7E) from the inhibi-
tory effect of Gamitrinib. To confirm that this response was specific, 
we next used ULK1-silenced tumor cells reconstituted with siRNA-
insensitive vectors. Expression of WT ULK1 in these cells restored the 
inhibition of tumor cell motility mediated by Gamitrinib (Figure 7F). 
In contrast, expression of non-AMPK phosphorylatable ULK1 
mutant (4SA) or a kinase-inactive (KI) ULK1 mutant was ineffective 
in the presence of Gamitrinib (Figure 7F). As control, reconstitution 
studies with the various siRNA-insensitive ULK1 cDNAs did not sig-
nificantly affect tumor cell proliferation (Figure 7G).
Figure 5
Metabolic stress control of cell motility. (A) NIH3T3 fibroblasts were transfected with vector or TRAP-1 cDNA, and analyzed by Western blotting. 
(B) The experimental conditions are as in A except that control or TRAP-1–transfected cells were analyzed for ATP production at the indicated 
glucose concentrations. LU, luciferase units. Mean ± SEM (n = 3). (C) NIH3T3 fibroblasts transfected as in A were analyzed by DAPI staining of 
invading cells under the indicated conditions. Right, quantification of cell invasion. Mean ± SEM (n = 3). **P = 0.0029; ***P < 0.0001. (D) NIH3T3 
fibroblasts transfected as in A were analyzed for cell proliferation. Mean ± SEM (n = 3). Original magnification, ×20.
Downloaded from http://www.jci.org on December  1, 2015.   http://dx.doi.org/10.1172/JCI67841
research article
2914 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013
In addition to atg13, ULK1 forms a complex with FIP200 (35), 
a molecule first identified as an endogenous inhibitor of FAK 
(36), and more recently implicated in autophagy (37), especially 
autophagosome formation (38, 39). Therefore, we next asked 
whether FIP200 functioned downstream of AMPK-ULK1 to con-
trol tumor cell motility. Consistent with this possibility, transfec-
tion of a FIP200 cDNA (Figure 8A) abolished tumor cell migration 
(Supplemental Figure 6D), and invasion (Figure 8A) compared 
with control transfectants. In contrast, tumor cell proliferation 
was not affected (Figure 8B). In reciprocal experiments, we silenced 
the expression of FIP200 using siRNA pools (Supplemental Fig-
ure 7A) or individual siRNA sequences (Figure 8C) and looked at 
tumor cell motility. In these studies, FIP200 knockdown reversed 
the inhibitory effect of Gamitrinib on tumor cell migration and 
Figure 6
LKB1/AMPK regulation of tumor cell motility. (A and B) LN229 cells were transfected with individual siRNA sequences to AMPK (A) or LKB1 
(B) and analyzed by Western blotting (top), cell migration (A), or invasion (B) with (+) or without (–) Gamitrinib (5 μM). Mean ± SEM (n = 3). 
**P = 0.0011; ***P < 0.0001. (C) LN229 cells were transfected with control siRNA or individual siRNA sequences to AMPK or LKB1 and analyzed for 
ATP production with (+) or without (–) Gamitrinib (5–10 μM). Mean of replicates of a representative experiment out of at least 3 independent deter-
minations. (D and E) Tumor cell types transfected with control or constitutively active AMPK (AMPKCA) cDNA were analyzed by Western blotting (D) 
or cell invasion (E). Mean ± SEM (n = 3). *P = 0.0295; ***P < 0.001. (F) The experimental conditions are as in D, except that transfected LN229 or 
PC3 cells were analyzed for ATP production. Mean ± SEM (n = 3). (G and H) PC3 cells were treated with rapamycin (Rapa, 0.1 μM) or Gamitrinib 
(5 μM), and analyzed by Western blotting for differential phosphorylation of the indicated kinases (G) or cell migration after 6 hours (H). Mean ± SEM 
(n = 3). (I and J) The indicated tumor cell lines were transfected with control siRNA or atg5-directed siRNA and analyzed by Western blotting (I) 
or cell invasion (J). Mean ± SEM (n = 3). **P < 0.001. (K) PC3 cells were transfected with control nontargeting siRNA or TRAP-1–directed siRNA 
alone or in combination with siRNA sequences directed to AMPK, atg5, or ULK1 and analyzed for cell migration. Mean ± SEM (n = 3). **P = 0.0022.
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invasion (Supplemental Figure 7B and Figure 8C), and restored the 
activating phosphorylation of FAK and Pak1, 2 (Ser144) compared 
with control siRNA transfectants (Figure 8D). The regulation of 
FIP200 function has not been completely elucidated, but may 
involve a ULK1-dependent phosphorylation step. Consistent with 
this model, FIP200 analyzed from Gamitrinib-treated cells exhib-
ited gel mobility retardation, suggestive of increased phosphoryla-
tion (Figure 8E), and, accordingly, reacted with an antibody to pan-
phosphorylated Ser (Figure 8E). Conversely, alkaline phosphatase 
treatment abolished Ser-phosphorylated reactivity with FIP200 
immunoprecipitated from Gamitrinib-treated PC3 cells (Fig-
ure 8F). Functionally, siRNA silencing of FIP200 (Figure 8G) 
rescued the tumor cell migration in TRAP-1–depleted cells (Figure 8H), 
mimicking the results obtained with Gamitrinib. In control exper-
iments, FIP200 or TRAP-1 silencing, alone or in combination, did 
not affect tumor cell proliferation (Figure 8I).
Mitochondrial Hsp90s control metastasis, in vivo. We next examined 
the impact of mitochondrial Hsp90 regulation of tumor cell motil-
ity in disease settings. First, we used a model of bone metastasis in 
which we silenced the expression of TRAP-1 in breast adenocar-
cinoma (AdCa) MDA-231 cells labeled with GFP (Figure 2A) and 
injected them in the left ventricle of immunocompromised mice to 
look at their dissemination to the knee joint after 72 hours. GFP+ 
cells transfected with nontargeting siRNA homed to the bone of 
Figure 7
ULK1 control of tumor cell motility. (A) PC3 cells were transfected with vector or constitutively active AMPK cDNA (AMPKCA) and analyzed by 
Western blotting for changes in phosphorylation of the indicated kinases. (B) PC3 cells were treated with vehicle, rapamycin (0.1 μM for 1 hour), 
metformin (5 mM for 6 hours), or Gamitrinib (5 μM for the indicated time intervals) and analyzed by Western blotting. (C) PC3 cells were treated 
with 17-AAG (5 μM) for the indicated time intervals and analyzed by Western blotting. (D) PC3 cells transfected with control or ULK1-directed 
siRNA were treated with (+) or without (–) Gamitrinib (5 μM) and analyzed by Western blotting for differential phosphorylation of the indicated 
kinases. (E) LN229 cells were transfected as in D and analyzed for cell migration (top) or invasion (bottom) in the presence (+) or absence (–) 
of Gamitrinib. Mean ± SEM (n = 3). ***P < 0.0001. (F) PC3 cells transfected with control siRNA or ULK1-directed siRNA were reconstituted with 
siRNA-insensitive WT ULK1, KI ULK1, or non-AMPK phosphorylatable ULK1 (4SA) cDNA and analyzed by Western blotting (top) or cell invasion 
(bottom). Mean ± SEM (n = 3). ***P < 0.0001. (G) The experimental conditions are as in F, except that transfected and reconstituted PC3 cells 
were analyzed for cell proliferation by direct cell counting. Mean ± SEM (n = 3).
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Immunoreactivity for phosphorylated ULK1 on Ser555 (Figure 9, E 
and F) or Ser757 (Figure 9, E and G) was also increased in NSCLC 
patients compared with normal lung, predominantly in AdCa 
(Figure 9, F and G). When stratified for disease outcome, phosphoryla-
tion of ULK1 on Ser757 was associated with shortened OS (Figure 9H, 
Supplemental Figure 8C, and Supplemental Table 2). This trend 
was mostly observed in patients with AdCa histotype (Supplemental 
Figure 8D) independently of tumor size or lymph node involvement 
(Supplemental Figure 8E). In these cases, preferential activation of 
the mTORC1 (Ser757) over AMPK (Ser555) pathway in ULK1 (31, 32) 
correlated with larger tumor size (Supplemental Figure 8F and Sup-
plemental Table 2), and decreased OS (Figure 9I).
Discussion
In this study, we have shown that tumor cells utilize mitochon-
drial Hsp90-directed protein folding (21) to produce ATP (23) 
under conditions of stress, such as nutrient deprivation or amino 
acid shortage (12). In spite of nutrient starvation, this adaptive 
injected animals as efficiently as nontransfected cultures (Figure 9, 
A and B). In contrast, siRNA silencing of TRAP-1 suppressed 
tumor cell localization to bone (Figure 9, A and B). In a second 
model of metastasis, we targeted the AMPK/ULK1 pathway, and 
we transfected lung AdCa H460 cells with ULK1 or constitutively 
active AMPKCA cDNA. Injection of cells transfected with control 
vector into the spleen of immunocompromised mice gave rise 
to extensive metastatic foci in the liver within 11 days (Figure 9, 
C and D). In contrast, transfection of AMPKCA or ULK1 cDNA 
reduced both the number and surface area of liver metastasis in 
reconstituted animals (Figure 9, C and D).
Based on these results, we next asked whether AMPK-ULK1 regula-
tion of cell motility was important in human tumors, and we studied 
a series of non–small cell lung cancer (NSCLC) patients with avail-
able clinical outcome data (Supplemental Table 1). ULK1 expression 
was elevated in NSCLC, especially AdCa histotypes, compared with 
squamous cell carcinoma (SCC) (Supplemental Figure 8A), but did 
not correlate with overall survival (OS) (Supplemental Figure 8B). 
Figure 8
FIP200 regulation of tumor cell motility. (A) PC3 cells were transfected with vector or FIP200 cDNA and analyzed by Western blotting (top) or cell 
invasion (bottom). Mean ± SEM (n = 3). ***P < 0.0001. (B) PC3 cells transfected as in A were analyzed for cell proliferation by direct cell counting. 
Mean ± SEM (n = 3). (C) PC3 cells were transfected with control siRNA or the indicated individual siRNA sequences to FIP200 and analyzed by 
Western blotting (top) or cell invasion (bottom) in the presence (+) or absence (–) of Gamitrinib. Mean ± SEM (n = 3). ***P < 0.0001. (D) PC3 cells 
were transfected with control siRNA or FIP200-directed siRNA and analyzed by Western blotting in the presence (+) or absence (–) of Gamitrinib. 
(E) PC3 cells were treated with vehicle or Gamitrinib (5 μM) and analyzed for gel mobility shift by Western blotting using antibodies to FIP200 
(left) or pan-phosphorylated Ser residues (right). Arrows, phosphorylated isotypes of FIP200. (F) FIP200 immune complexes precipitated from 
Gamitrinib-treated PC3 cells were incubated with (+) or without (–) alkaline phosphatase (AP) and analyzed by Western blotting. (G) PC3 cells 
were transfected with control siRNA, FIP200- or TRAP-1–directed siRNA alone or in combination and analyzed by Western blotting. (H and I) The 
PC3 cells transfected as in G were analyzed for cell migration (H) or cell proliferation by direct cell counting (I). Mean ± SEM (n = 3). ***P < 0.0001.
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translated to enhanced tumor cell invasion, in vivo, metastatic 
dissemination to bone or liver in mouse models of disease, and 
shortened OS in patients with NSCLC (Figure 10).
The crosstalk between bioenergetics stress imposed by nutrient 
deprivation, activation of AMPK, and induction of autophagy in 
the dynamics of tumor growth is complex and likely carries differ-
ent functional implications depending on disease stage and cellular 
context. Accordingly, these mechanisms have been variously linked 
mechanism is sufficient to dampen the activation of the energy 
sensor and tumor suppressor AMPK (14, 15) and limit the induc-
tion of another tumor-suppression mechanism, autophagy (ref. 18 
and Figure 10). When analyzed in the context of cell movements, 
this pathway maintained cytoskeletal dynamics through persis-
tent phosphorylation of multiple cell motility kinases and released 
FAK (25, 26) from inhibition by an ULK1-FIP200 autophagy-ini-
tiating complex (refs. 38, 39, and Figure 10). Functionally, this 
Figure 9
Metabolic control of metastasis. (A) Representative image of single GFP-labeled breast AdCa MDA-231 cells (arrows) lodged near the growth 
cartilage of the femora and tibiae of inoculated CB17 SCID mice. Original magnification, ×100 (left). (B) Quantification of bone homing of GFP-
labeled MDA-231 cells transfected with control siRNA or TRAP-1–directed siRNA. Mean ± SEM (5 animals/group). *P = 0.034. None, untrans-
fected cells. (C) Representative histologic image of livers from animals injected intrasplenically with H460 cells transfected with vector, AMPKCA 
or ULK1 cDNA. Original magnification, ×1. (D) Quantification of number of metastatic foci (top) and metastatic surface area (bottom) per each 
condition tested. Mean ± SEM (3–4 animals/group). ***P < 0.0001; **P = 0.009. (E) Representative images of immunohistochemical expression 
of ULK1-Ser555 or ULK1-Ser757 in NSCLC TMA sections. Middle panels, representative sections of normal lung weakly positive (<10% stained 
cells) for ULK1-Ser757 expression. Original magnification, ×50 (left panels); ×200 (right panels). (F and G) Summary of ULK1-Ser555 (F) or 
ULK1-Ser757 (G) immunoreactivity in NSCLC patients. The analysis parameters are as follows: (F) ULK1-Ser555, n = 173; positive, 98 (AdCa), 
40 (SCC); negative, 20 (AdCa), 15 (SCC); (G) ULK1-Ser757 (cytosolic reactivity), n = 178; positive, 38 (AdCa), 5 (SCC); negative, 83 (AdCa), 52 
(SCC). (H and I) Kaplan-Meier survival curves of NSCLC patients according to expression of Ser757-phosphorylated ULK1 (H) or differential ratio 
(cutoff, 0.2) of Ser757/Ser555- phosphorylated ULK1 (I).
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sive network and enables FAK-dependent tumor cell invasion in 
the face of nutrient deprivation. Mechanistically, this pathway 
involves retention of the first enzyme of the glycolytic cascade, 
HK-II, to the mitochondrial outer membrane (4) via regulation of 
CypD folding (23). However, other mechanisms of energy produc-
tion are also plausible, and galactose challenge experiments pre-
sented here pointed to a role of mitochondrial Hsp90s in main-
taining a residual level of oxidative phosphorylation, consistent 
with a role of these molecules in oxygen consumption (23).
The pathogenetic context for these observations (Figure 10) 
resides in the highly unfavorable conditions of tumor growth in 
vivo, chronically depleted of oxygen and nutrients and constant-
ly exposed to oxidative stresses (12). Despite these challenges, a 
nutrient-impaired microenvironment has been causally linked to 
tumor progression (1), and, accordingly, mitochondrial Hsp90-
directed bioenergetics under energy deprivation enabled meta-
static dissemination in vivo. Conversely, loss of TRAP-1 expression 
in mitochondria or gain of activity by the autophagy regulators, 
AMPK or ULK1 antagonized tumor cell motility and suppressed 
metastatic dissemination in mice. Despite the ambivalent nature 
of autophagy in tumor progression (17), there is now considerable 
effort to target the regulators of this pathway for cancer therapy. 
Our data highlight the complexity of this approach and suggest 
that disabling autophagy-initiating molecules, in particular ULK1, 
may have detrimental contraindications, not only by removing 
to tumor suppression (40) or, conversely, cell survival under meta-
bolic stress (41) or tumor adaptation (18). Our results show that 
AMPK activation, while potentially important for cell survival (41), 
also provides a strong barrier against tumor cell motility and metas-
tasis in a pathway reversed by mTORC1 activation (15). This model 
is in line with developmental roles of AMPK (42) and LKB1 (43) in 
epithelial polarity and cytoskeletal remodeling during metabolic 
stress (44) and antimetastatic properties proposed for LKB1 (45).
A key effector of tumor cell motility under nutrient deprivation 
downstream of AMPK was identified here as the ULK1-FIP200 
complex (32). Together with atg13, this multiprotein interactor 
functions as an upstream initiator of autophagy (37, 38), poten-
tially coordinating the process of autophagosome formation (38). 
How FIP200 is regulated in this complex is still being worked out, 
but there is evidence for a role of ULK1-mediated phosphoryla-
tion (39) consistent with our findings that ULK1 kinase activity 
is required for tumor cell motility and that FIP200 exhibits phos-
phorylation-dependent gel retardation in energy-impaired tumor 
cells. In parallel with its role in autophagy (38), activated FIP200 
also functions as an endogenous inhibitor of FAK (37), shutting 
off the multifunctional properties of this kinase in cell motility, 
invasion, proliferation, and survival (25) that are often exploited 
in disparate cancers (26).
Mitochondrial Hsp90-directed bioenergetics emerged here as an 
adaptive mechanism that overcomes this global tumor-suppres-
Figure 10
Schematic representation of bioenergetics stress control of tumor cell motility. (A) Inhibition of mitochondrial Hsp90-directed protein folding 
by Gamitrinib induces a bioenergetics imbalance due to detachment of HK-II from the mitochondrial outer membrane. In turn, this results in 
decreased ATP production, activation of the energy sensor LKB-1-AMPK kinase cascade, and AMPK-dependent phosphorylation of ULK1, a 
component of the upstream autophagy initiator complex. Active ULK1 mediates phosphorylation and activation of FIP200, which in turn inhibits 
FAK-directed tumor cell motility and metastasis. (B) Despite limited nutrient availability, mitochondrial Hsp90s maintain HK-II tethered to the 
organelle outer membrane and potentially maintain a residual mitochondrial oxidative phosphorylation capacity. In turn, energy produced under 
these conditions is sufficient to prevent activation of LKB1/AMPK signaling, blocking the formation of a phosphorylation-dependent, active ULK1-
FIP200-atg13 complex. This prevents the initiation of autophagy and releases FAK from the inhibitory effect of phosphorylated FIP200, promoting 
cell motility and metastasis. PTP, permeability transition pore; cyto c, cytochrome c.
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concentration in each extract was determined in a microplate luminometer 
(Beckman Coulter) against standard ATP solutions used as a reference.
Animal models of skeletal or liver metastasis. All experiments in vivo were car-
ried out in accordance with the Guide for the Care and Use of Laboratory 
Animals of the NIH. Protocols were approved by an IACUC. For an ani-
mal model of skeletal metastasis (51, 52), 5-week-old female CB17-SCID 
mice were obtained from Taconic and housed in a germ-free barrier. At 
6 to 8 weeks of age, mice were anesthetized with the combined adminis-
tration of ketamine (80 mg/kg) and xylazine (10 mg/kg) administered by 
intraperitoneal route and then inoculated in the left cardiac ventricle with 
breast AdCa MDA-231 cells. Cell inoculation was performed using an insu-
lin syringe with a 30-gauge needle. The correct penetration of the cardiac 
wall was established by the appearance of fresh arterial blood in the Luer-
Lok fitting of the hypodermic needle. In addition, blue-fluorescent polysty-
rene beads (10 μm diameter; Invitrogen, Molecular Probes) were coinjected 
with cancer cells and their detection in the adrenal glands was utilized to 
confirm successful inoculation in the blood circulation (51, 52). Animals 
were sacrificed after 72 hours, and adrenal glands and bones were fixed 
in 4% formalin for 48 hours. Femora and tibiae were decalcified in 0.5 M 
EDTA for 4 days, and tissues were frozen in O.C.T. embedding medium 
(Electron Microscopy Sciences) after a cryoprotection step in 25% sucrose 
for 24 hours. Serial tissue sections of 80-μm thickness were prepared using 
a Microm HM550 cryostat (Mikron). Sections of each hind leg and soft-tis-
sue organs were transferred on glass slides, stored at –20°C, and examined 
for cancer cells using a Zeiss AX10 fluorescence microscope connected to 
a Nuance multispectral imaging system (CRI) with a measurement mod-
ule included in the analysis software (v. 2.4). Bright field and fluorescence 
images were acquired with an Olympus DT70 CCD color camera (51, 52).
For an animal model of liver metastasis (53), 6- to 8-week-old female 
SCID/beige mice were anesthetized with ketamine hydrochloride; the 
abdominal cavity was exposed by laparotomy and injected into the spleen 
with 4 × 106 H460 cells previously transfected with control plasmid, ULK1 
cDNA, or constitutively active AMPKCA cDNA. Spleens were removed the 
following day to minimize effects on metastasis due to variable growth of 
primary tumors. Animals were sacrificed at 11 days after injection, and 
their livers were resected, fixed in formalin, and paraffin embedded. Liver 
sections were stained with H&E and analyzed histologically. Metastatic 
foci were quantified in serial tissue sections by histology and expressed as 
number of lesions and surface areas of tumor growth (53).
Patient samples. Samples from a series of 180 consecutive patients surgi-
cally treated for NSCLC at Fondazione IRCCS Ca’ Granda Hospital between 
2000 and 2004 were available for this study. This patient series included 123 
cases of AdCa and 57 cases of SCC of the lung. Clinical outcome data were 
available for all patients. NSCLC cases were staged according to the current 
TNM classification of malignant tumors (54). The follow-up period ranged 
from 0 to 132 months (average 55.2 months). At the last follow-up (January 
2011), 103 patients were deceased from progression of NSCLC, whereas 77 
patients were alive. Patients’ characteristics are summarized in Supplemen-
tal Table 1. Supplemental Methods are available online.
Statistics. Data were analyzed using 2-sided unpaired t tests using a 
GraphPad software package (Prism 4.0) for Windows. For analysis of 
patient samples, groups were compared using Student’s t tests as univari-
ate statistics. For OS analysis, the Kaplan-Meier method was used. Patients 
negative for ULK1-Ser757 were plotted separately from ULK1-Ser757–pos-
itive cases, and the 2-sided log-rank test was used to compare the 2 curves. 
The phosphorylation event at Ser757 or Ser555 had opposite effects on 
ULK1 function. When the immunoreactivity of both phosphorylated 
forms was considered, a score was computed for each sample summing 
Ser757 immunoreactivity in the cytoplasm and in nuclei and dividing for a 
Ser555 immunoreactivity value. Kaplan-Meier curves for patient OS under 
autophagy-associated tumor cell death (17), but also by unre-
straining FAK from FIP200 inhibition (36), promoting paradoxi-
cal tumor cell invasion and metastasis.
As a pivotal effector of this response, there is evidence that ULK1 
regulation is achieved by differential phosphorylation, but con-
troversy exists as to the reciprocal roles of AMPK or mTORC1 
kinases in this process (35) and whether these modifications have 
disease relevance in vivo. The data here suggest that a relative ratio 
of ULK1 phosphorylation on putative AMPK (Ser555) (31, 32) 
or mTORC1 (Ser757) (31) site(s) may better predict downstream 
responses of autophagy and, consequently, tumor cell motility and 
invasion. This approach may have clinical utility, as we observed 
that preferential ULK1 phosphorylation by mTORC1 over AMPK 
correlates with disease progression and shortened OS in NSCLC 
patients. These data are consistent with a role of mTORC1 sig-
naling (15) as a disease driver and potential therapeutic target in 
lung cancer (46), and suggest that AMPK activation in established 
malignancies in vivo may continue to provide a tumor suppressor 
function, possibly linked to activation of autophagy (14) and inhi-
bition of metastasis (this study).
In sum, mitochondrial Hsp90-directed tumor cell metabolism 
(23) functions as a pivotal mediator of tumor cell motility and 
invasion when nutrients are scarce, consistent with the nearly 
ubiquitous overexpression of these chaperones in advanced dis-
ease in vivo (21). Although there has been considerable progress in 
mapping the transcriptional requirements of metastasis (47) and 
the cellular (48) and genetic (49, 50) aspects of this process have 
come into better focus, disseminated tumors are incurable, carry-
ing considerable morbidity and mortality. Instead, subcellular tar-
geting of mitochondrial Hsp90s as upstream regulators of tumor 
bioenergetics (Figure 10) is feasible (30) and may simultaneously 
disable key signaling nodes of tumor energy production (23) and 
cell survival (21), indispensable for metastatic competency, in vivo.
Methods
Cell culture. Human glioblastoma LN229, prostate AdCa PC3 and PC3-ML 
subline, lung AdCa H1299, H1437, H460, and A549, breast AdCa MDA-
MB-231, melanoma 1205Lu, and WM793, or normal NIH3T3 and 
MRC-5 fibroblasts were obtained from ATCC and maintained in culture 
according to the supplier’s specifications. For metabolic stress experi-
ments, cells were incubated in MEM-based medium containing glucose, 
essential and nonessential amino acids, and vitamin concentrations iden-
tical to those of DMEM, plus 4 mM L-glutamine, 1 mM sodium pyruvate, 
10 mM HEPES, and 10% 10 K dialyzed FBS (Gibco; Invitrogen). Three 
conditions were tested: 25 mM glucose (complete medium), 5 mM glu-
cose, or 50% amino acid deprivation compared with DMEM. Galactose 
challenge experiments were performed by culturing the cells in DMEM 
No Glucose Medium supplemented with 4 mM L-glutamine, 10% 10-K 
dialyzed FBS, and the indicated mixtures of D-(+)-glucose and D-(+)-
galactose to a final concentration of 25 mM.
Protein analysis. Protein lysates were prepared in RIPA buffer containing 
150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 
and 50 mM Tris, pH 8.0, in the presence of EDTA-free protease inhibi-
tor cocktail (Roche) and phosphatase inhibitor cocktail 2 and 3 
(Sigma-Aldrich). Equal amounts of protein lysates were separated by SDS 
gel electrophoresis, transferred to PVDF membranes, and incubated with 
primary antibodies of various specificities. Protein bands were detected by 
chemiluminescence, as described (21).
ATP measurement. Intracellular ATP concentrations were measured by the 
luciferin-luciferase method using an ATP measuring kit (Biochain). The ATP 
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